Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSVildagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4; Ki = 0.003 µM).1 It is selective for DPP-4 over DPP-2, DPP-8, and DPP-9 (Kis = >500, 0.81, and 0.095 µM, respectively). Vildagliptin (3 mg/kg) decreases plasma glucose levels and increases plasma insulin levels during an oral glucose challenge in Zucker fa/fa rats.2 It prevents increases in liver triglyceride and thiobarbituric acid reactive substance (TBARS) levels in a mouse model of non-alcoholic fatty liver disease (NAFLD) induced by a high-cholesterol diet.3 Formulations containing vildagliptin have been used in the treatment of type 2 diabetes.
WARNING This product is not for human or veterinary use.
1. Discovery of 3H-
2. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-
3. Anti-